Therapies that block adenosine triphosphate (ATP) can reduce the irritation that causes cough, and some currently being studied also don’t have taste side effects that can confound clinical trial results, explained Ron Eccles, BSc, PhD, DSc, emeritus profess at Cardiff University.
Therapies that block adenosine triphosphate (ATP) can reduce the irritation that causes cough, and some currently being studied also don’t have taste side effects that can confound clinical trial results, explained Ron Eccles, BSc, PhD, DSc, emeritus profess at Cardiff University.
Transcript
How do drugs being studied in clinical trials better address cough than over-the-counter medications that have a placebo-like effect on cough?
The ATP is believed to be released as part of an inflammatory reaction and stimulate nerve endings, peripheral nerve endings, to induce cough. Therefore, if you can block the effects of ATP, you can reduce the amount of coughing, reduce the amount of irritation—that sensory irritation that causes cough. That is the idea behind it. So yes, it's a very interesting pharmacological approach to treating cough.
A big advantage also is that, apart from the taste side effects, which confound the clinical trials, these medicines don't enter the central nervous system and don't cause any sedation or other side effects. So, it's a very interesting area. And if one could antagonize ATP, without the side effects associated with taste, we'd have a very good medicine.
So, in the future, there may be more specific ATP antagonists that don't affect taste so much and which will provide benefit that can be demonstrated in these clinical trials.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More